The broad protection of these patents opens doors to partnerships in the world’s second- and third-largest pharmaceutical markets NORCROSS, Ga. , Jan. 25, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics , Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to
NORCROSS, Ga. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at BIO CEO & Investor Conference on Tuesday,
NORCROSS, Ga. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at the 30th Annual ROTH Conference on March 12, 2018
NORCROSS, Ga. , March 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced March 26, 2018 is the record date for the 2018 Annual Meeting of Stockholders to be held on May 22, 2018 in Atlanta, GA.
NORCROSS, Ga. , March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin , the Company’s Chief Operating Officer, will present at the 2 nd Annual H.C.
NORCROSS, Ga. , March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will participate in two upcoming international conferences in
NORCROSS, Ga. , March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2017 . These results are included in the Company's Annual Report on Form
NORCROSS, Ga. , April 02, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at the H.C.
GR-MD-02 treatment in NASH cirrhosis patients without esophageal varices shows statistically significant and clinically meaningful effects NORCROSS, Ga. , April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. ( NASDAQ:GALT ) , the leading developer of therapeutics that target galectin
NORCROSS, Ga. , April 16, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today provided highlights from a late-breaker oral presentation at The International Liver Congress™ 2018 , European Association for the
